You just read:

Merrimack Completes Enrollment in Randomized Phase 2 SHERLOC Study of MM-121 (seribantumab) in Non-Small Cell Lung Cancer (NSCLC)

News provided by

Merrimack Pharmaceuticals, Inc.

Sep 06, 2018, 06:50 ET